摘要
目的研究胰腺癌患者血清特征性N-糖链结构变化规律,期望找到胰腺癌特异性血清标志物。方法选取2011年6月至2013年12月在哈尔滨医科大学附属第三医院就诊的胰腺癌患者,将检测对象分成胰腺癌患者术前血清组(123例)与术后血清组(78例)。选取体检中心收集的健康人群血清样本271例作为健康人血清组。应用基于DNA测序仪的荧光糖电泳(DSAFACE)技术比较分析3组血清中N-糖链的变化。计量资料以均数±标准差(x±s)表示,2组间比较采用成组t检验。结果通过对血清N-糖链的DSA-FACE分析,确定了胰腺癌患者血清N-糖链谱图,在此基础上比较分析胰腺癌患者术前、术后血清与健康人血清的N-糖链变化。糖峰8在胰腺癌患者术前组显著低于健康人群组(t=2.735,P<0.05)及术后组(P<0.05),而术后组与健康组差异无统计学意义。结论糖峰8可以成为辅助的胰腺癌诊断标志糖链。
Objective To investigate the structural changes in specific serum N-glycans in pancreatic cancer patients and to identify the specific serum maker of pancreatic cancer.Methods The pancreatic cancer patients who visited the Third Affiliated Hospital of Harbin Medical University from June 201 1 to December 2013 were assigned to preoperative serum group (123 cases)and postoperative serum group (78 cases);healthy controls whose serum samples were collected in the Physical Examination Center were selected as control serum group (271 cases).DNA sequencer-aided fluorophore-assisted carbohydrate electrophoresis (DSA-FACE)was used to analyze serum N -glycans and compare them between the three groups.Results The serum N-glycan profiles in pancreatic cancer patients were identified by DSA-FACE.The results indicated that N-glycan peak 8 in preoperative serum group was significantly lower than those in control serum group (t=2.735,P〈0.05)and postoperative serum group (P〈0.05),but no significant difference was found between the postoperative serum group and control serum group.Conclusion N-glycan peak 8 can be considered as a serum marker of pancreatic cancer.
出处
《临床肝胆病杂志》
CAS
2014年第8期749-751,共3页
Journal of Clinical Hepatology
基金
黑龙江省自然科学基金资助项目(D200926)